Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Gates Announces Secondary Offering and Share Repurchase Program

Elaine Mendonca by Elaine Mendonca
February 13, 2024
in Breaking News
0
Technology Cloud computing
0
SHARES
6
VIEWS
Share on FacebookShare on Twitter

On February 13, 2024, Gates Industrial Corporation plc (NYSE:GTES), widely recognized as Gates, made a significant announcement regarding a secondary offering. The offering entails the sale of 17,500,000 ordinary shares by certain selling stockholders affiliated with Blackstone Inc. This exciting opportunity also includes a provision that grants underwriters a 30-day option to purchase an additional 2,625,000 ordinary shares.

The selling of these shares can take place in various avenues, including the New York Stock Exchange, the over-the-counter market, negotiated transactions, or any other method that aligns with market prices or negotiated prices. The offering is expected to conclude on February 16, 2024, pending customary closing conditions. It is important to note that Gates will not be participating in this offering and will not receive any proceeds from the sale of shares.

Citigroup, Goldman Sachs & Co. LLC, and Jefferies have been appointed as the joint lead book-running managers for this offering. Additionally, Barclays, Morgan Stanley, UBS Investment Bank, BMO Capital Markets, Evercore ISI, Mizuho, and RBC Capital Markets will also serve as joint book-running managers. This collaboration among esteemed financial institutions highlights the significance of this offering.

In conjunction with its existing share repurchase strategy, Gates has also unveiled a share repurchase program. This program demonstrates the company’s commitment to enhancing shareholder value and further strengthens their position in the market.

GTES Stock Analysis: Price Decrease and Trading Range Overview – February 13, 2024

On February 13, 2024, GTES stock opened at $12.53, which was $0.27 lower than its previous close. The stock experienced a price decrease of $0.10 since the market last closed, representing a drop of 0.74%. Trading in the middle of its 52-week range suggests that GTES has not reached any extreme highs or lows within the past year. Additionally, being above its 200-day simple moving average is generally considered a positive sign. While a decrease of $0.10 may seem insignificant, it is worth noting that even small price movements can have a significant impact, especially for investors with large positions. However, it is crucial to remember that stock prices are influenced by various factors, and further research and analysis should be conducted to evaluate GTES’s financial health, growth prospects, and any recent developments that may have influenced its stock price. Investors should consult with a financial advisor or conduct thorough research before making any investment decisions.

GTES Stock Performance: Mixed Results with Fluctuating Net Income and Stable Revenue

On February 13, 2024, GTES stock performance showcased a mixed picture. Despite holding flat in terms of total revenue since the previous year and quarter, the company experienced a slight increase in net income compared to the previous year, but a decrease from the previous quarter. Earnings per share (EPS) also saw positive growth from the previous year but remained unchanged from the previous quarter.

GTES reported $3.57 billion in total revenue in the past year and $863.30 million in the fourth quarter. The company’s total revenue remained flat compared to the previous year and quarter.

GTES recorded $233.50 million in net income in the past year and $63.00 million in the fourth quarter. Net income increased by approximately 5.56% compared to the previous year but decreased by 20.05% compared to the previous quarter.

GTES reported $0.85 in earnings per share (EPS) in the past year and $0.24 in the fourth quarter. EPS increased by approximately 10.13% compared to the previous year but remained unchanged from the previous quarter.

Overall, GTES’s stock performance on February 13, 2024, showcased a mixed bag of results. While total revenue held steady, net income experienced fluctuations, and EPS showed positive growth but remained unchanged from the previous quarter. Investors and analysts may monitor GTES closely to evaluate the reasons behind the fluctuating net income and its potential impact on the company’s future performance.

Tags: GTES
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
The Rise of Enterprise Business Intelligence Platforms: Transforming Operations in the Healthcare Sector

BIOLASE Inc Announces Details of Public Offering

Healthcare Services Stock Exchange

InMode Reports Strong Financial Performance and Market Reaction

Biochemistry and biomedicines

JetBlue Airways Stock Soars Amidst Carl Icahns Investment and Merger Controversy

Recommended

Gold Stock

Gold Nears Historic Peak as Market Anticipation Builds

2 months ago
Dentist

Advancements in Oral Healthcare: The Business Impact of Highly Trained Surgeons

2 years ago
Archer Aviation Stock

Archer Aviation Strengthens Market Position Through Strategic Patent Acquisition

4 months ago
SNDR stock news

Yousif Capital Management LLC Reduces Stake in Steven Madden, Ltd.: Implications for the Company’s Future Performance

3 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Blue Ridge Bankshares Emerges from Regulatory Challenges with Return to Profitability

Navigating the Interest Rate Tightrope: Bank7’s Path Forward

Trending

Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

by Rodolfo Hanigan
February 7, 2026
0

Investor attention is turning to the upcoming catalysts for Design Therapeutics, a biotechnology firm advancing its GeneTAC...

Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

February 7, 2026
Graftech Stock

Graftech Shares Plunge on Bleak Quarterly Results

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding
  • Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy
  • Repay Holdings: Annual Report to Test Strategic Refinancing Success

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com